Your session is about to expire
← Back to Search
Venetoclax + Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
Study Summary
This trial is testing a new combination therapy to treat people with a certain type of leukemia that has relapsed or is resistant to treatment. The goal is to find the best dose of the new combination therapy that doesn't cause severe side effects. The trial will also measure how well the new combination therapy works.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 389 Patients • NCT02005471Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have an active severe infection or it is under control.I cannot take medications by mouth due to a digestive condition.I don't have ongoing major side effects from cancer treatment.I have been diagnosed with acute promyelocytic leukemia.My white blood cell count is high and I need treatment to lower it.I have not taken any experimental drugs in the last 4 weeks.I cannot or do not want to have a bone marrow test.I have hepatitis B or C but my viral load is undetectable, or I've been vaccinated against HBV.I have undergone more than three different treatment plans for my condition.I am willing to use effective birth control during and after my treatment.I am not pregnant and can prove it with a test taken in the last week.I have a history of serious heart issues, including CHF or angina.I am between 18 and 75 years old.I have had a condition where small veins in my liver were blocked.My leukemia cells show CD33 expression in at least 20% of blasts.My leukemia has spread to my brain or spinal cord.I have taken GO or Venetoclax before, and my cancer does not have p53 mutations.I finished my last cancer treatment over 21 days ago and have recovered from its side effects.My AML has returned or is not responding to treatment, and I've had prior therapy.I haven't taken strong or moderate CYP3A affecting drugs in the last week, unless my doctor said it was necessary.I haven't had cancer, except for certain skin cancers or treated early-stage cancers, in the last year.I had a stem cell transplant less than 2 months ago.I have a history of blood disorders like myelofibrosis or leukemia.I can care for myself and am up and about more than 50% of my waking hours.You have eaten grapefruit, grapefruit products, Seville oranges (including marmalade with Seville oranges), or starfruit within 3 days before starting the study treatment.I can understand and follow the study's procedures.My recent tests show my organs are functioning well.
- Group 1: Gemtuzumab Ozogamicin(GO) + Venetoclax
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there other investigations involving the drug Venetoclax?
"Presently, 243 studies involving Venetoclax are active with 31 of them in the third phase. While most research on this medication is based out of Antwerpen and New york, there are a total 7775 locations running these trials across the globe."
Has the Federal Drug Administration sanctioned Venetoclax for public use?
"Our team at Power has assigned Venetoclax a score of 1 based on its Phase 1 classification, indicating that there is only limited data available to assess both safety and efficacy."
Are participants still being accepted into this experiment?
"According to clinicaltrials.gov, this experiment is still gathering participants since its original posting on September 6th 2019 and latest update on November 18th 2022."
How many participants are being recruited for this research?
"This trial requires 24 eligible patients and has two confirmed locations: the Indiana University Melvin and Bren Simon Comprehensive Cancer Center in Indianapolis, IN and the University of Nebraska Medical Center in Omaha, NE."
In which locations is the clinical experiment being conducted?
"The 4 sites recruiting participants for this research trial are Indiana University Melvin and Bren Simon Comprehensive Cancer Center in Indianapolis, University of Nebraska Medical Center in Omaha, Univeristy of Illinois in Chicago, as well as another four different locations."
What maladies is Venetoclax regularly employed to treat?
"Venetoclax has been demonstrated to effectively treat individuals with a fresh diagnosis of small lymphocytic lymphoma or chronic lymphocytic leukemia (CLL)."
Share this study with friends
Copy Link
Messenger